Olié Valérie, Cheddani Lynda, Stengel Bénédicte, Gabet Amélie, Grave Clémence, Blacher Jacques, Halimi Jean-Michel
Santé publique France, Direction des maladies non transmissibles et traumatismes, 12, rue du Val-D'Osne, 94415 Saint-Maurice, France.
Centre de diagnostic et de thérapeutique, Hôtel-Dieu, Paris, France; Université de Paris, Paris, France.
Nephrol Ther. 2021 Dec;17(7):526-531. doi: 10.1016/j.nephro.2021.05.006. Epub 2021 Oct 8.
The epidemiology of chronic kidney disease remains poorly described in France despite its burden. The objective of our study was to provide an estimate of the prevalence of chronic kidney disease stades 3-5 (without replacement therapy) in France.
The data come from the Esteban study carried out in France between 2014 and 2016 on a representative sample of the French population. This study included 3,021 adults between 18 and 74 years old. Of these, 2422 adults (80.2%) had serum creatinine assay and were included in this analysis. Renal function was estimated by calculating glomerular filtration rate using the Chronic kidney disease epidemiology collaboration (CKD-Epi) and European Kidney function consortium (EKFC) equations.
The means glomerular filtration rate in our population were respectively 97.5 and 89.0 mL/min/1.73 m with the CKD-EPI and EKFC equations. The prevalence of chronic renal failure, defined by a glomerular filtration rate less than 60 mL/min/1.73 m was 1.5% with the CKD-EPI formula and 2.1% with the EKFC formula in adults aged 18 to 74 years. The prevalence was higher in women than in men and increased with age, reaching 6.5% and 9.9% in 65-74 years with the CKD-EPI and EKFC equations, respectively. After extrapolation to the French population, the number of adults with chronic kidney disease stades 3-5 without renal replacement therapy was around 1.6 million.
In France, the prevalence of chronic kidney disease stades 3-5 without renal replacement therapy was between 1.5 and 2.1% of the adult population aged 18 to 74.
尽管慢性肾脏病负担沉重，但在法国其流行病学情况仍鲜为人知。我们研究的目的是估计法国慢性肾脏病3 - 5期（未接受替代治疗）的患病率。
数据来自于2014年至2016年在法国开展的埃斯特班研究，该研究选取了具有代表性的法国人群样本。这项研究纳入了3021名18至74岁的成年人。其中，2422名成年人（80.2%）进行了血清肌酐检测并纳入本分析。使用慢性肾脏病流行病学协作组（CKD - Epi）和欧洲肾功能联盟（EKFC）公式通过计算肾小球滤过率来评估肾功能。
采用CKD - EPI和EKFC公式时，我们研究人群的平均肾小球滤过率分别为97.5和89.0毫升/分钟/1.73平方米。在18至74岁的成年人中，肾小球滤过率低于60毫升/分钟/1.73平方米定义的慢性肾衰竭患病率，采用CKD - EPI公式时为1.5%，采用EKFC公式时为2.1%。女性患病率高于男性，且随年龄增长而增加，在65 - 74岁人群中，采用CKD - EPI和EKFC公式时患病率分别达到6.5%和9.9%。 extrapolation（外推）到法国总人口后，未接受肾脏替代治疗的慢性肾脏病3 - 5期成年人数约为160万。
在法国，未接受肾脏替代治疗的慢性肾脏病3 - 5期患病率在18至74岁成年人口的1.5%至2.1%之间。
